Canada gets tough on ultrasound systems
This article was originally published in Clinica
The Canadian Therapeutic Products Directorate, the regulatory agency for medical devices, has announced that it has upgraded the risk classification of diagnostic ultrasound systems and transducers from class II to class III. The decision takes effect on July 1 2002 and is consistent, the Directorate states, with those in other regulatory jurisdictions.
You may also be interested in...
US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.
Sabinsa provided FDA and FTC with documentation of “an ingredient falsely marketed and sold as vitamin C derived from amla fruit (Emblica officinalis), which two independent labs have confirmed is actually derived from corn, sugarcane or other plants.”
With its US/Mexico Phase III trial delayed due to manufacturing questions, Novavax has aligned its UK study with FDA guidance. It hopes for interim data from that study during Q1 2021.